

# ANMC Non-occupational Post-exposure Prophylaxis (nPEP) – Adults and Adolescents

Recommended Populations	Testing before and following nPEP			
<ul style="list-style-type: none"> <li>• Within 72 hours of an isolated incident of high risk HIV exposure, treatment should be initiated as soon as possible</li> <li>• Potential exposures to consider and recommend nPEP:                             <ul style="list-style-type: none"> <li>○ Sexual assault</li> <li>○ Unprotected sex with new partner of unknown HIV status</li> <li>○ Use or injury with needle or syringe used previously by another person</li> </ul> </li> <li>• Not generally recommended for:                             <ul style="list-style-type: none"> <li>○ History of sustained active injection drug use (discuss PrEP)</li> <li>○ Frequent recent high risk sexual exposures (discuss PrEP)</li> </ul> </li> </ul>		Baseline	4-6 weeks	3 months
	HIV Ag/Ab	X	X	X
	Hep B surface Ag Hep B surface Ab Hep B core Ab	X		
	Hep C Ab <sup>a</sup>	X		
	Syphilis <sup>b</sup>	X	X	
	Gonorrhea <sup>b</sup>	X		
	Chlamydia <sup>b</sup>	X		
	Pregnancy <sup>b</sup>	X	X	
	Renal Function (Serum Creatinine)	X		
	Liver Function (AST/ALT)	X		
	a – If blood exposure repeat Hepatitis C Ab at 6 months b – If sexual exposure			

## Treatment Recommendations

Preferred Regimen		Education
Adults and adolescents ≥13 yo with normal renal function including pregnant females	<ul style="list-style-type: none"> <li>• <b>Tenofovir disoproxil fumarate/Emtricitabine</b> 300mg/200mg PO daily x 28 days</li> <li><b>PLUS</b></li> <li>• <b>Dolutegravir</b> 50 mg PO daily x 28 days</li> </ul>	<ul style="list-style-type: none"> <li>• Treatment should not be delayed if waiting on non-rapid HIV Ag/Ab testing results</li> <li>• Follow up with ID or Primary Care within 3-5 days for continuation of prescription and arrangement of appropriate follow up plan</li> <li>• Preventive treatment is discontinued after 28 days</li> </ul>
Adults and adolescents ≥13 yo with renal dysfunction (CrCl <60 mL/min)	<ul style="list-style-type: none"> <li>• <b>Zidovudine and Lamivudine</b> dose adjust to renal function x 28 days</li> <li><b>PLUS</b></li> <li>• <b>Dolutegravir</b> 50 mg PO daily x 28 days</li> </ul>	

ANMC Associated Powerplans: Orders for Sexual Assault Response, AMB HIV and STI Post-exposure Prophylaxis

Antimicrobial Stewardship Program Approved April 2021

**References:** Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. CDC/HHS. Accessed March 4, 2021.